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In this case report we provide evidence that supports a link between mycobacteria and Crohn’s disease. The patient in question,
KG, presented on three separate occasions over a ten years period with features suggestive of intestinal tuberculosis. He was treated
successfully on each occasion with antimycobacterial drugs. When he presented a fourth time with the same symptoms, he was
diagnosed with Crohn’s disease based on findings from endoscopy, histology and CT. Subsequently he was treated with a course of
steroids and made a full recovery. This case adds weight to the theory that mycobateria has an aetiological role in Crohn’s disease.
1. Introduction
Crohn’s disease (CD) is an inflammatory disorder of the gas-
trointestinal tract characterised by transmural inflammation.
The cause of Crohn’s disease remains unknown; however, it
is increasingly recognised that mucosal inflammation results
from a dysfunctional innate immune response in susceptible
individuals. Enteric microorganisms are thought to play a
pivotal role in the initiation and maintenance of inflamma-
tion, although a specific infectious agent remains elusive. The
similarities between Crohn’s disease and Johne’s disease, a
chronic enteritis aﬀecting cattle and other ruminants caused
by Mycobacterium avium paratuberculosis (MAP) [1], have
led observers to suggest a link between Crohn’s disease and
mycobacteria.
There is microbiological and serological evidence of an
association of MAP with CD. MAP has been cultured in 50%
of blood samples of patients with CD, as compared with 20%
of patients with ulcerative colitis and 0% of controls [2].
MAP has also been cultured from mucosal biopsies from a
greater proportion of CD patients (42%) than from controls
(9%) [3]. MAP antibodies have also been found with greater
frequency in CD than in control [4]. However, the lack of
eﬃcacy of antituberculous therapy in CD has limited any
suggestions of causality. In this report we present a case of
CD treated with antituberculous therapy, and we review the
evidence for a causal role of MAP in CD.
2. Case Presentation
KG, a 42-year-old Indian male, presented in 1995 with
abdominal pain exacerbated by eating, anorexia, and weight
loss. He had travelled to India 5 years previously, and
he was known to have beta thalassaemia trait. There was
no history of fevers or diarrhoea. He remained afebrile
during his inpatient stay. Gastroscopy, colonoscopy, small
bowel meal, and barium enema were normal. Early morning
urine samples, and Mantoux test, did not demonstrate
evidence of tuberculosis. Furthermore, bone marrow biopsy
showed leukopenia and thrombocytosis, with no organisms
present on culture. His initial blood tests confirmed a
thrombocytosis with a platelet count of 645 × 109/L. His
haemoglobin was 12.0 g/dL, and his ESR was elevated at
64 mm/hr.
In our experience, the diagnosis of tuberculous enteritis
frequently remains challenging despite the investigations
described above. Several authorities recommend initiating
antituberculous therapy if there is a strong clinical suspicion
of tuberculosis despite nondiagnostic histological or bac-
teriological studies [5]. Whilst laparoscopy and mesenteric
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sampling have a higher sensitivity, these patients frequently
respond rapidly to medical therapy and, thus, laparoscopy
is usually considered if improvement is not seen after two
weeks. In this case, due to the patient’s marked systemic
inflammation, Indian origin, and lack of evidence for
alternative diagnoses such as lymphoma or inflammatory
bowel disease, he was commenced on empirical antitubercu-
lous treatment with rifampicin, isoniazid, ethambutol, and
pyrazinamide. He gained weight rapidly, and his blood tests
returned to normal. He received eight and a half months of
treatment.
He relapsed the following year with abdominal pain,
vomiting, and fever. CT of the abdomen demonstrated
an abnormal terminal ileum and caecum, suggestive of
tuberculosis, inflammatory bowel disease, or lymphoma. A
small bowel meal confirmed an irregular thickening in the
terminal ileum. However bone marrow aspirate and periph-
eral cultures proved unremarkable, with no evidence of
mycobacteria. A diagnostic laparoscopy was recommended,
but the patient declined this procedure. A further course
of antituberculous therapy with the same regimen again
provided a dramatic therapeutic response. He received a year
of treatment.
Five years later, a further recurrence of symptoms
occurred. He was worked up in an identical fashion with
colonoscopy, abdominal CT, and barium meal and follow-
through. The only positive finding was on CT, which
demonstrated a featureless terminal ileum, despite the wall
being of normal thickness with no fat stranding. On this
occasion the patient again declined diagnostic laparoscopy.
Again, he responded to empirical antituberculous therapy,
although a laparoscopy was not performed. A further
three years later, he again presented with a recurrence
of his symptoms, CT showed thickening of the terminal
ileum (Figure 1), and colonoscopy demonstrated multiple
erosions in the terminal ileum (Figure 2). Biopsies did not
demonstrate granulomata but highlighted patchy acute
and chronic inflammation with inflammatory cell infiltrate
consistent with Crohn’s disease. Prolonged microbiological
culture of ileal specimens was also negative. On this occasion,
a course of steroids for Crohn’s disease was prescribed and,
again, he made a dramatic recovery.
3. Discussion
Crohn’s disease is considered to be a disease of unknown
aetiology, which is increasing in incidence in developed
countries. This case report provides anecdotal evidence that
supports a link between mycobacteria and Crohn’s disease.
Over a period of ten years, KG presented intermittently with
fatigue, diarrhoea, abdominal pain, and weight loss. On
the fourth episode, he was diagnosed with Crohn’s disease
after suggestive features on endoscopy, histology, and CT,
leading to a course of steroids and full recovery. However
KG went into remission on three previous episodes, for
one, five, and three years, respectively, after a course of
antituberculous therapy (rifampicin, isoniazid, ethambutol,
and pyrazinamide). This adds weight to a body of evidence
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Figure 1: Thickening of terminal ileum and mesenteric lym-
phadenopathy.
Figure 2: Multiple erosions in the terminal ileum seen at
colonoscopy.
that postulates mycobacteria as an aetiological agent in
Crohn’s disease.
Dalziel described a chronic, interstitial enteritis two
decades before the report by Crohn and colleagues [6].
He also noted the similarities between Crohn’s disease and
Johne’s disease in cattle. Johne’s disease is characterised
by granuloma formation, transmural inflammation, and
involvement of adjacent lymphoid tissue [7]. MAP fulfils
Koch’s postulates as the causative organism, since it has
been identified in diseased cattle, cultured, and shown to
reinfect healthy animals. MAP has also been shown to cause
ileocolitis in primates [8].
However, the evidence that MAP causes intestinal disease
in humans is inconsistent. Case reports of immunosup-
pressed patients and children have demonstrated diﬀuse
MAP infection in humans [9, 10]. Indeed, a six-year-old
boy developed typical ileocaecal Crohn’s disease, five years
after treatment for MAP lymphadenitis [7]. Despite these
cases, eﬀorts to identify organisms in histological specimens
from patients with Crohn’s disease have been disappointing.
This is in contrast to Johne’s disease, where the organism
may occasionally be seen. A possible reason for this is
the fastidious nature of the organism, which is diﬃcult
to grow in vitro [11]. Unlike M. Tuberculosis, MAP may
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be present in its cell-wall deficient form in humans. In
this sense, the disease may resemble paucibacillary lep-
rosy, rather than tuberculosis. In cell-wall deficient states,
typical staining for acid and alcohol fast bacilli is likely
to be negative. Other laboratory techniques, identifying
DNA- , RNA- , or MAP-specific proteins, show significant
interlaboratory variation which may represent environmen-
tal contamination or technical diﬃculties. Bernstein and
colleagues have reported an increased seroprevalence of
MAP in Crohn’s disease measured by ELISA [12], although
this finding has not been replicated with diﬀerent MAP
antigens.
Several investigators have studied the eﬀects of antimy-
cobacterial therapy in CD. Initial, open-label studies of
antimycobacterial therapy in CD suggested a possible ther-
apeutic benefit. In 1994, Mor and colleagues [13] showed
that the most eﬀective regimen for the treatment of M.
avium infection is a combination of macrolide antibiotics
and rifabutin. In 1997, Gui et al. [14] described the results
of treatment of Crohn’s disease with clarithromycin or
azithromycin and rifabutin. They called their treatment
RMAT (rifabutin and macrolide antibiotic therapy). Of
the 46 patients who tolerated RMAT for 6–35 months, 43
(94%) went into clinical remission. This was associated with
a reduction in the Crohn’s disease activity index (CDAI)
and inflammatory parameters. In addition, only 2 of 19
patients who were steroid dependent at the beginning of
the study continued to require steroids. However, controls
were not used in this study. In 1999, Douglass and colleagues
[15] reported a 6-month open pilot study of 20 patients
treated with rifabutin, clarithromycin, and clofazimine.
Twelve (60%) of the 20 patients who were steroid dependent,
refractory, or requiring surgery were in remission by 6
months. Shafran et al. [16] reported an open trial of RMAT
with a probiotic in 36 patients with active Crohn’s disease.
Of the patients who tolerated treatment, 58% achieved a
decrease in CDAI of 70 points and did not require steroids
or immunosuppressants. Borody et al. [17] also treated 12
patients with rifabutin, clarithromycin and clofazimine for
6–54 months. Six of the 12 (50%) achieved complete clinical,
colonoscopic, and histological remission.
These four, small studies suggest that half of patients with
active Crohn’s disease, who can tolerate long-term antibiotic
therapy, will achieve remission. These figures are higher
than published data for steroids, immunomodulators, or
the ACCENT trials for infliximab [18]. However, a recent,
well-designed, randomised, and placebo-controlled trial of
clarithromycin, rifabutin, and ethambutol failed to show
a sustained benefit in CD [19]. Although the antibiotic
regimen showed a benefit at week 16, in addition to
corticosteroid therapy, this eﬀect was lost over the 2-year
trial period. However, the presence or absence of MAP in
these patients was not assessed and there is therefore no
evidence that MAP was cleared by treatment. Moreover,
the doses of rifabutin (450 mg), clarithromycin (750 mg),
and clofazimine (50 mg) in this trial are below the optimal
doses for MAP treatment, and resistance may also have
developed over the three-year period despite the use of three
drugs.
4. Conclusion
In conclusion, the case presented above is an example of
anecdotal experience from many physicians of the response
of CD to antimycobacterial therapy. On the back of recent
insights into the complex epithelial interface between the
gut mucosa and intestinal microbiota [20], a causal role
for MAP in patients with genetic susceptibility to microbial
persistence remains a possibility to be explored. This case
study demonstrated that the patient suﬀered relapses at least
three times which were treated successfully with antimy-
cobacterial drugs. This suggests that the patient was most
likely reinfected with the microorganism. MAP after all is
present in pasteurised milk and meat.
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